BIIB Novinky na Forexu
Biogen Q2 Results Top Estimates; Boosts FY24 Outlook
Biotechnology company Biogen Inc. (BIIB) reported Thursday net income attributable to the company for the second quarter of $583.6 million or $4.00 per share, higher than $591.6 million or $4.07 per share in the prior-year quarter.
RTTNews
|
Před 95 dny
Biogen Says European Commission Grants TOFIDENCE Biosimilar Approval For Multiple Indications
Biogen Inc. (BIIB) announced Monday that the European Commission (EC) has granted approval for TOFIDENCETM, a biosimilar monoclonal antibody referencing ROACTEMRA.
RTTNews
|
Před 133 dny
Biogen To Buy Human Immunology Biosciences In Deal Valued At Up To $1.8 Bln
Biogen Inc. (BIIB) and privately-held biotechnology company Human Immunology Biosciences or HI-Bio, announced Wednesday the companies have entered into a definitive agreement under which Biogen has agreed to acquire HI-Bio for $1.15 billion upfront and up to $650 million in potential milestone payments.
RTTNews
|
Před 166 dny
Biogen Q1 Adj. EPS Tops Estimates, But Sales Miss; Reaffirms FY24 Outlook
Biotechnology company Biogen Inc. (BIIB) reported Wednesday net income attributable to the company for the first quarter of $393.4 million or $2.70 per share, higher than $387.9 million or $2.67 per share in the prior-year quarter.
RTTNews
|
Před 194 dny
Biogen Says European Commission Revokes Marketing Authorizations For Generic Versions Of TECFIDERA
Biotechnology company Biogen, Inc. (BIIB) announced Tuesday that the European Commission has revoked the centralized marketing authorizations for generic versions of Biogen's product TECFIDERA (dimethyl fumarate) held by Accord, Mylan, Neuraxpharm, Polpharma and Teva.
RTTNews
|
Před 321 dny
Biogen Q2 Results Top Estimates; Backs FY23 Outlook
Biotechnology company Biogen, Inc. (BIIB) reported Tuesday that net income attributable to the company for the second quarter plunged to $591.6 million or $4.07 per share from $1.06 billion or $7.24 per share in the prior-year quarter.
RTTNews
|
Před 468 dny
Biogen Q1 Results Top Estimates; Reaffirms FY23 Outlook
Biotechnology company Biogen Inc. (BIIB) reported Tuesday net income attributable to the company for the first quarter of $387.9 million or $2.67 per share, higher than $303.8 million or $2.06 per share in the prior-year quarter.
RTTNews
|
Před 559 dny
Biogen Q4 Results Top Estimates
Biotechnology company Biogen Inc. reported Wednesday that profit for the fourth quarter surged 50 percent from last year, reflecting lower expenses despite a 7 percent revenue growth. However, adjusted earnings per share and quarterly revenues topped analysts' expectations. The company also initiated adjusted earnings and revenue growth guidance for the full-year 2023, in line with estimates.
RTTNews
|
Před 628 dny
Biogen Appoints Christopher Viehbacher As President And CEO
Biotechnology company Biogen Inc. (BIIB) announced Thursday that its Board of Directors has appointed Christopher Viehbacher as President and Chief Executive Officer and a member of the Board of Directors, effective November 14. Viehbacher succeeds Michel Vounatsos, who has led the company since 2017.
RTTNews
|
Před 725 dny
Biogen Boosts FY22 Outlook As Q2 Results Top Estimates
While reporting financial results for the second quarter on Wednesday, Biogen Inc. (BIIB) raised its adjusted earnings and revenue guidance for the full-year 2022, based on better-than-expected topline performance and continued cost management.
For fiscal 2022, the company continues to project adjusted earnings in the range of $15.25 to $16.75 per share on revenues between $9.90 billion and $10.1 billion.
RTTNews
|
Před 838 dny
